Kilitch Drugs (India) Limited approved the appointment of CA Sujit Kumar Dash as a Chief Financial Officer of the Company at its SBM held on February 12, 2019.

The company announced unaudited standalone earnings results for third quarter and nine months ended December 31, 2018. For the quarter, the company reported net sales/income from operations were INR 193.272 million against net sales/income from operations of INR 130.54 million a year ago. Total income from operations was INR 196.546 million against total income from operations of INR 131.042 million a year ago. Net profit after tax for the period from continuing operations was INR 34.585 million against net profit after tax for the period from continuing operations of INR 17.955 million a year ago. Basic earnings per share was INR 2.14 against basic earnings per share of INR 1.36 a year ago.

For the period, the company reported net sales/income from operations were INR 740.206 million against net sales/income from operations of INR 347.6 million a year ago. Total income from operations was INR 786.026 million against total income from operations of INR 365.839 million a year ago. Net profit after tax for the period from continuing operations was INR 121.142 million against net profit after tax for the period from continuing operations of INR 39.129 million a year ago. Basic earnings per share was INR 8.38 against basic earnings per share of INR 2.96 a year ago.